Guidance on Waiver of In-Vivo Bioequivalence Requirements. December 2015 - Ethiopia
(2015; 36 pages)

EFMHACA would like to acknowledge the United States Agency for International Development (USAID) and the U. S. Pharmacopeial Convention Promoting the Quality of Medicines Program (USP PQM) for the financial and technical support delivered in preparation of this Guidance on Waiver of In vivo Bioequivalence Requirements.

Resumen

This document is intended to provide guidance on biowaiver implementation under The Ethiopian Food, Medicine and Health Care Administration and Control Authority (EFMHACA). The requirements set in this guidance document are applicable to new applications for registration of a pharmaceutical product based BCS classifications, dose proportionate formulation (usually for lower strengths) and variation to registered products which have systemic action of oral solid dosage form. Suspensions should be treated in the same way as for immediate release solid oral dosage form. Multisource products as described in section 1 of Annex IV: requirement for bioequivalence study of Guideline for Registration of Medicines (EFMHACA), 2014 their availability are self- evidence and not require bioequivalence study are not covered in guidance document. Locally acting medicines such as locally acting antacids and anti-helminthic do not require bioequivalence study are not covered in this guidance document.

 
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019